VERTEX PHARMACEUTICALS INC / MA — Operating Income by Fiscal Year
18 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/87f2bec7-f28c-4e1f-bad1-036277c67376/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $4.2B | 2025-01-01 – 2025-12-31 | evidence 0000875320-26-000056 |
| FY 2024 | $-232.9M | 2024-01-01 – 2024-12-31 | evidence 0000875320-25-000053 |
| FY 2023 | $3.8B | 2023-01-01 – 2023-12-31 | evidence 0000875320-24-000062 |
| FY 2022 | $4.3B | 2022-01-01 – 2022-12-31 | evidence 0000875320-23-000007 |
| FY 2021 | $2.8B | 2021-01-01 – 2021-12-31 | evidence 0000875320-22-000007 |
| FY 2020 | $2.9B | 2020-01-01 – 2020-12-31 | evidence 0000875320-22-000007 |
| FY 2019 | $1.2B | 2019-01-01 – 2019-12-31 | evidence 0000875320-22-000007 |
| FY 2018 | $635.1M | 2018-01-01 – 2018-12-31 | evidence 0000875320-19-000006 |
| FY 2017 | $123.2M | 2017-01-01 – 2017-12-31 | evidence 0000875320-18-000009 |
| FY 2016 | $9.9M | 2016-01-01 – 2016-12-31 | evidence 0000875320-17-000017 |
| FY 2015 | $-466.9M | 2015-01-01 – 2015-12-31 | evidence 0000875320-16-000067 |
| FY 2014 | $-692.4M | 2014-01-01 – 2014-12-31 | evidence 0000875320-15-000012 |
| FY 2013 | $-610.0M | 2013-01-01 – 2013-12-31 | evidence 0000875320-15-000012 |
| FY 2012 | $46.7M | 2012-01-01 – 2012-12-31 | evidence 0000875320-15-000012 |
| FY 2011 | $113.8M | 2011-01-01 – 2011-12-31 | evidence 0001047469-12-001298 |
| FY 2010 | $-696.1M | 2010-01-01 – 2010-12-31 | evidence 0001047469-11-001025 |
| FY 2009 | $-614.0M | 2009-01-01 – 2009-12-31 | evidence 0001047469-11-001025 |
| FY 2008 | $-462.7M | 2008-01-01 – 2008-12-31 | evidence 0001047469-11-001025 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
VERTEX PHARMACEUTICALS INC / MA — all facts · Revenue · Net Income